---
title: "ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295237160.md"
description: "Atossa Therapeutics reported a Q2 2026 net loss of $8.49M and diluted EPS of $(0.95). Cash reserves stood at $26.1M, with the company expressing substantial doubt about its ability to continue as a going concern. The firm advanced its (Z)-endoxifen program across four Phase 2 trials, secured orphan drug designations for DMD and MAS, and completed a $4.0M capital raise to support operations."
datetime: "2026-08-07T12:41:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295237160.md)
  - [en](https://longbridge.com/en/news/295237160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295237160.md)
generator: "portal-rs"
---

# ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q Summary

Atossa Therapeutics, Inc. reported a net loss for the second quarter of 2026, with net loss of $(8.49M) and diluted loss per share of $(0.95). Cash and cash equivalents totaled $26.1M at June 30, 2026, and the company disclosed substantial doubt about its ability to continue as a going concern.

**Financial Highlights**

-   Net income: $(8.49M) loss for Q2 2026, compared with $(8.42M) loss in Q2 2025.
-   Diluted EPS: $(0.95) for Q2 2026, versus $(0.98) in the year-ago quarter.
-   Cash & liquidity note: Cash and cash equivalents $26.1M at June 30, 2026 (working capital $25.6M); company reports substantial doubt about going concern.

**Business Highlights**

-   Clinical program progress: Advanced (Z)-endoxifen across four Phase 2 trials (Karisma, I-SPY, RECAST, EVANGELINE) with ongoing enrollments and expected data readouts in H2 2026.
-   Clinical efficacy signals: Reported biological activity including reduced mammographic breast density, Ki-67 suppression, MRI tumor volume reductions and ctDNA clearance.
-   Regulatory & orphan designations: Secured Rare Pediatric Disease and Orphan Drug designations for DMD and a Rare Pediatric Disease designation for MAS, supporting potential PRV value.
-   Manufacturing & IP: Established a proprietary manufacturing process, multiple dosage strengths, seven U.S. and 16 international patents with protection through at least 2038.
-   Capital raises & runway: Completed a $4.0M registered direct offering and initiated an ATM program to support near-term operations and upcoming trial milestones.

Original SEC Filing: ATOSSA THERAPEUTICS, INC. \[ ATOS \] - 10-Q - Aug. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ATOS.US](https://longbridge.com/en/quote/ATOS.US.md)

## Related News & Research

- [Paratus Energy announces Q2 2026 cash dividend of USD 0.22 per share](https://longbridge.com/en/news/297268195.md)
- [VER: Q2 2026 delivered 6.5% like-for-like revenue growth and strong gross margin, with 2026 guidance reaffirmed](https://longbridge.com/en/news/297124510.md)
- [Cemat publishes H1 2026 interim report](https://longbridge.com/en/news/297006906.md)
- [Omda to present Q2 2026 results via webcast](https://longbridge.com/en/news/297024929.md)
- [Perma-Pipe International - Enters 2026 Credit Agreement With JPMorgan Chase Bank On August 25, 2026 - SEC Filing](https://longbridge.com/en/news/297184704.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**